R&D Pipeline

 

Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of cancer, autoimmune disorders, and chronic inflammatory conditions. 

Nektar is also engaged in a series of co-development and commercialization collaborations with pharmaceutical industry leaders and emerging biotech companies.

Therapeutic Area
Condition/Disease
Agents
Mechanism
Phase
Partner
Genitourinary Cancer
Locally Advanced or Metastatic Urothelial Carcinoma
NKTR-255 + Bavencio®
Phase 2
Agent(s) NKTR-255 + Bavencio®
STUDY JAVELIN Bladder Medley
+
Hematological Cancer
Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NKTR-255 + RITUXAN® or DARZALEX FASPRO®
Phase 1/2
Agent(s) NKTR-255 + RITUXAN® or DARZALEX FASPRO®
+
Solid Tumors
Metastatic Colorectal Cancer or Metastatic Head and Neck Cancer
NKTR-255 + ERBITUX®
Phase 1/2
+
Autoimmune Disorders
Systemic Lupus Erythematosus
NKTR-358
Phase 2
Agent(s) NKTR-358
STUDY ISLAND-SLE
+
Autoimmune Disorders
Psoriasis
NKTR-358
Phase 1B
Agent(s) NKTR-358
+
Autoimmune Disorders
Atopic Dermatitis
NKTR-358
Phase 1B
Agent(s) NKTR-358
+
Immuno-Oncology
NKTR-288
Preclinical
Agent(s) NKTR-288
+
Autoimmune Disorders
TNFR antibody
Bivalent Agonistic Antibody Targeting TNFR2
Preclinical
Agent(s) TNFR antibody
Mechanism Bivalent Agonistic Antibody Targeting TNFR2
+